85 related articles for article (PubMed ID: 23065008)
1. Live and let (MPN cells) die!
Cassinat B; Kiladjian JJ
Blood; 2012 Oct; 120(15):2933-4. PubMed ID: 23065008
[No Abstract] [Full Text] [Related]
2. Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-α 2a specifically targets JAK2V617F-positive polycythemia vera cells.
Lu M; Wang X; Li Y; Tripodi J; Mosoyan G; Mascarenhas J; Kremyanskaya M; Najfeld V; Hoffman R
Blood; 2012 Oct; 120(15):3098-105. PubMed ID: 22872685
[TBL] [Abstract][Full Text] [Related]
3. The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon α 2a target JAK2V617F-positive progenitor and stem cells.
Lu M; Xia L; Li Y; Wang X; Hoffman R
Blood; 2014 Jul; 124(5):771-9. PubMed ID: 24869939
[TBL] [Abstract][Full Text] [Related]
4. p53 at the crossroads of MPN treatment.
Plo I
Blood; 2014 Jul; 124(5):668-9. PubMed ID: 25082860
[TBL] [Abstract][Full Text] [Related]
5. Treatment with the Bcl-xL inhibitor ABT-737 in combination with interferon α specifically targets JAK2V617F-positive polycythemia vera hematopoietic progenitor cells.
Lu M; Wang J; Li Y; Berenzon D; Wang X; Mascarenhas J; Xu M; Hoffman R
Blood; 2010 Nov; 116(20):4284-7. PubMed ID: 20625010
[TBL] [Abstract][Full Text] [Related]
6. Pegylated interferon Alfa-2a and hydroxyurea in polycythemia vera and essential thrombocythemia: differential cellular and molecular responses.
Tashi T; Swierczek S; Kim SJ; Salama ME; Song J; Heikal N; King KY; Hickman K; Litton S; Prchal JT
Leukemia; 2018 Aug; 32(8):1830-1833. PubMed ID: 29556018
[No Abstract] [Full Text] [Related]
7. A novel application for murine double minute 2 antagonists: the p53 tumor suppressor network also controls angiogenesis.
Binder BR
Circ Res; 2007 Jan; 100(1):13-4. PubMed ID: 17204660
[No Abstract] [Full Text] [Related]
8. P53 activation inhibits all types of hematopoietic progenitors and all stages of megakaryopoiesis.
Mahfoudhi E; Lordier L; Marty C; Pan J; Roy A; Roy L; Rameau P; Abbes S; Debili N; Raslova H; Chang Y; Debussche L; Vainchenker W; Plo I
Oncotarget; 2016 May; 7(22):31980-92. PubMed ID: 26959882
[TBL] [Abstract][Full Text] [Related]
9. Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance.
McCubrey JA; Abrams SL; Ligresti G; Misaghian N; Wong EW; Steelman LS; Bäsecke J; Troppmair J; Libra M; Nicoletti F; Molton S; McMahon M; Evangelisti C; Martelli AM
Leukemia; 2008 Nov; 22(11):2080-90. PubMed ID: 18685611
[TBL] [Abstract][Full Text] [Related]
10. Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo.
Verger E; Soret-Dulphy J; Maslah N; Roy L; Rey J; Ghrieb Z; Kralovics R; Gisslinger H; Grohmann-Izay B; Klade C; Chomienne C; Giraudier S; Cassinat B; Kiladjian JJ
Blood Cancer J; 2018 Oct; 8(10):94. PubMed ID: 30287855
[TBL] [Abstract][Full Text] [Related]
11. Nutlin kills cancer cells via mitochondrial p53.
Morselli E; Galluzzi L; Kepp O; Kroemer G
Cell Cycle; 2009 Jun; 8(11):1647-8. PubMed ID: 19448434
[No Abstract] [Full Text] [Related]
12. Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma.
Van Maerken T; Speleman F; Vermeulen J; Lambertz I; De Clercq S; De Smet E; Yigit N; Coppens V; Philippé J; De Paepe A; Marine JC; Vandesompele J
Cancer Res; 2006 Oct; 66(19):9646-55. PubMed ID: 17018622
[TBL] [Abstract][Full Text] [Related]
13. Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells.
Mir R; Tortosa A; Martinez-Soler F; Vidal A; Condom E; Pérez-Perarnau A; Ruiz-Larroya T; Gil J; Giménez-Bonafé P
Int J Cancer; 2013 Apr; 132(7):1525-36. PubMed ID: 22961628
[TBL] [Abstract][Full Text] [Related]
14. Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer.
Zanjirband M; Edmondson RJ; Lunec J
Oncotarget; 2016 Jun; 7(26):40115-40134. PubMed ID: 27223080
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of bone marrow morphology is essential for assessing disease status in recombinant interferon α-treated polycythemia vera patients.
Margolskee E; Krichevsky S; Orazi A; Silver RT
Haematologica; 2017 Mar; 102(3):e97-e99. PubMed ID: 27810993
[No Abstract] [Full Text] [Related]
16. [In-vivo activation of the p53 pathway by small-molecule antagonists of MDM2].
Shinohara T; Uesugi M
Tanpakushitsu Kakusan Koso; 2007 Oct; 52(13 Suppl):1816-7. PubMed ID: 18051440
[No Abstract] [Full Text] [Related]
17. Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination.
Cheok CF; Dey A; Lane DP
Mol Cancer Res; 2007 Nov; 5(11):1133-45. PubMed ID: 18025259
[TBL] [Abstract][Full Text] [Related]
18. MDM2 antagonist can inhibit tumor growth in hepatocellular carcinoma with different types of p53 in vitro.
Wang J; Zheng T; Chen X; Song X; Meng X; Bhatta N; Pan S; Jiang H; Liu L
J Gastroenterol Hepatol; 2011 Feb; 26(2):371-7. PubMed ID: 21261729
[TBL] [Abstract][Full Text] [Related]
19. Efficient activation of p53 pathway in A549 cells exposed to L2, a novel compound targeting p53-MDM2 interaction.
Zhang L; Zhang J; Hu C; Cao J; Zhou X; Hu Y; He Q; Yang B
Anticancer Drugs; 2009 Jul; 20(6):416-24. PubMed ID: 19579266
[TBL] [Abstract][Full Text] [Related]
20. MDM2 antagonism by nutlin-3 induces death in human medulloblastoma cells.
Ghassemifar S; Mendrysa SM
Neurosci Lett; 2012 Mar; 513(1):106-10. PubMed ID: 22343310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
